Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.

Rheumatology (Oxford) · 2019 · PMC6880852 · PMID 31184752

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

During the extension period, mean ESR and mean concentrations of CRP, anti-cyclic citrullinated peptide and rheumatoid factor maintained a decreasing trend; mean decreases from baseline in these variables were similar in each treatment group.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.